Pipeline / 02 · Infectious Disease

HIV Functional Cure Program

An integrated therapeutic approach combining tri-specific antibodies, CAR-like NK effectors, AH-D peptide activation, and GEDM-3DQ-guided coordination.

MECHANISM OF ACTION A four-pronged attack on HIV. i. Prevent New Infection AH-D peptide and HIV-IFN constructs bind viral gp120 with high affinity, blocking entry into new host cells. ii. Eliminate Circulating Virus T cell engager (TCE) mechanism redirects activated T cells to precisely eliminate free HIV virions in the blood. iii. Eradicate Viral Reservoirs Activated T cells and NK cells are guided to eliminate HIV-infected reservoir cells throughout the body — the key barrier to cure. iv. Restore Immune Function Promotes T cell and NK cell proliferation, restoring CD4 counts to normal levels (>450/μL) even in severely immunocompromised patients.
The integrated HIV platform addresses all four therapeutic requirements: preventing new infection, eliminating circulating virus, eradicating viral reservoirs, and restoring immune reconstitution.
Premise

The problem we are solving.

After four decades, HIV remains incurable because of a single biological challenge: the latent reservoir. Infected cells go dormant, invisible to the immune system, invisible to antiretrovirals — waiting. Any therapy that only suppresses active virus leaves the reservoir intact.

A functional cure requires three things to happen together: the reservoir must be woken up, the now-visible infected cells must be tagged, and specialized immune effectors must eliminate them before they re-hide. Each step exists in isolation today. None works reliably alone.

THE BURDEN · CURRENT REALITY A crisis that no current therapy resolves. 39.9M people living with HIV GLOBAL 1.5M new infections ANNUALLY 630K AIDS-related deaths ANNUALLY 9.3M without lifesaving treatment STILL
The HIV/AIDS global burden — 39.9M people living with HIV, 1.5M new infections and 630K AIDS-related deaths annually, with 9.3M still without access to lifesaving treatment. A functional cure remains medically undefined today.
Approach

How we tackle it.

MACRO HRD's HIV program integrates all four platform technologies against a single coordinated objective. AH-D peptide penetrates latently infected cells and activates dormant provirus. Tri-specific antibodies recognize the now-exposed infected cells, bridge them to immune effectors, and prevent escape. CAR-like NK cells and γδ T cells execute the cytotoxic elimination. GEDM-3DQ coordinates timing, dose, and sequence across all four interventions in real time.

The program is developed in partnership with the Ragon Institute of Mass General, MIT and Harvard, and with Prof. Veron Ramsuran at the University of KwaZulu-Natal. Target populations include sub-Saharan African cohorts where HIV burden is highest, using topical gel and spray formulations for mucosal prevention alongside systemic cure protocols.

MULTI-STEP MECHANISM OF ACTION Five interventions, orchestrated in sequence. 01 AH-D Priming Membrane disruption opens infected cells 02 gp120 Binding Trispecific antibody recognizes viral envelope 03 T Cell Redirect TCE bridges effector to infected target 04 IFN Signaling Type I interferon amplifies immune response 05 Reconstitution CD4/NK proliferation restored to baseline Each step orchestrated by GEDM-3DQ in real-time response to patient state.
Multi-step mechanism of action. Each modality addresses a specific stage of the HIV lifecycle, with GEDM-3DQ coordinating the sequence of intervention — AH-D membrane disruption, tri-specific antibody engagement, T cell redirection, and immune reconstitution.
Capabilities

What makes this real.

01
Reservoir activation
AH-D peptide penetrates latently infected cells and activates dormant provirus — the first step no single-modality therapy achieves.
02
Infected-cell tagging
Tri-specific antibodies recognize and mark activated cells for immune elimination while preventing viral escape.
03
Coordinated cytotoxic clearance
CAR-like NK and γδ T cells eliminate tagged cells before reservoir re-establishment, guided by GEDM-3DQ timing.
04
Mucosal topical delivery
Gel and spray formulations for female genital tract — prevention and early post-exposure intervention at the primary transmission site.
PRECLINICAL & CLINICAL EVIDENCE Reservoir cells eliminated, not suppressed. RESERVOIR CD4⁺ T CELLS Baseline 100% Post-treatment <1% INDEPENDENT VALIDATION Humanized mouse models PHE / Public Health England HIV reservoir reactivation Validated across multiple organ sites Half-life: 4-6 hr · IC₅₀: 250 fg/mL Measured under physiological conditions Tissue distribution to CNS Confirmed via PET imaging in NHP
Preclinical and clinical evidence on viral reservoir elimination. Independent third-party validation in humanized mouse models; ongoing clinical data from cohorts reaching viral loads below detectable thresholds.
Where It Connects

Part of an integrated platform.

01 · Platforms
Functional Peptide Platform
A library of 20,000+ engineered peptides for membrane penetration, targeted delivery, and biological modulation.
01 · Platforms
Multi-Specific Antibody Platform
Tri-specific antibody systems for precision targeting, immune recruitment, and viral escape prevention.
01 · Platforms
Engineered Immune Cells Platform
CAR-like NK systems and γδ T cell therapies for adaptive, MHC-independent elimination of diseased cells.
01 · Platforms
GEDM-3DQ Decision Engine
Gradient Equilibrium Decision Modeling in 3-Dimensional Quadrant — the AI spine of every MACRO HRD program.
⸻ Continue the platform

“A functional cure is not one breakthrough. It is four, arriving together, in the right order.”

See all ventures → Engage with MACRO HRD